Jabbour, E. J., Sasaki, K., Ravandi, F., Short, N. J., Garcia‐Manero, G., Daver, N., Kadia, T., Konopleva, M., Jain, N., Cortes, J., Issa, G. C., Jacob, J., Kwari, M., Thompson, P., Garris, R., Pemmaraju, N., Yilmaz, M., O'Brien, S. M., & Kantarjian, H. M. (2019). inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 125(15), 2579–2586. http://access.bl.uk/ark:/81055/vdc_100087074687.0x00005a